Latest News

Shilpa Medicare receives EIR from USFDA

Shilpa Medicare has received establishment inspection report (EIR), from United States Food and Drug Administration (USFDA).

The company has received of EIR for both API manufacturing facilities located at Raichur, Karnataka, from USFDA. This inspection was carried out between 16 to 19 January, 2018 and the inspection has now been closed by USFDA.

Read EquityPandit’s Technical Analysis of Nifty Pharma

Click here to check market prediction for next trading session.

Get Daily Prediction & Stocks Tips On Your Mobile


I would like to receive communication from EquityPandit via sms, email, whatsapp, Google RCS for offers, updates etc.



📰
News
📈
Prediction
📊
FII / DII
👔
Advisory
Get 1-2 Index Option Trades Daily